<?xml version="1.0" encoding="UTF-8"?>
<p id="p0120">There has been unprecedented fast track path taken in R&amp;D by the World community for developing candidate COVID-19 vaccines. As of 5 May 2020, the global COVID-19 vaccine R&amp;D includes 108 candidate vaccines.
 <xref rid="bib71" ref-type="bibr">
  <sup>71</sup>
 </xref> The platform for 108 candidate vaccines are diverse and include live-attenuated vaccine (n = 3), inactivated vaccine (n = 7), DNA vaccine (n = 10), RNA vaccine (n = 16), replicating viral vector vaccine (n = 12), nonreplicating viral vector vaccine (n = 15), protein subunit vaccine (n = 36), virus-like particles (n = 6), and unknown (n = 3). These platforms have been used in the past in 45 instances against a variety of infectious pathogens (
 <xref rid="tbl2" ref-type="table">Table 2</xref>).
</p>
